This segment explores Dr. Rossi's clinical experience with cilta-cel as a second-line therapy, focusing on its efficacy and quality-of-life benefits across diverse patient populations.
Video content above is prompted by the following:
Can you share your experience with cilta-cel as a second-line therapy?
What advantages in terms of efficacy and quality of life have you noted across various patient populations?